ArticleClinical rheumatology2019
The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.Dermatology and therapy · 2026Review
- Invasive Rhinocerebral Mucormycosis Is a Rare Complication in Systemic Juvenile Idiopathic Arthritis PatientTurkish archives of pediatrics · 2025Article
- Unveiling the differences: infection disorders associated with tumor necrosis factor α inhibitors in pediatric patients-a pharmacovigilance study (2004-2023).European journal of pediatrics · 2025Article
- Influenza knowledge and barriers to vaccination in immunosuppressed patients in the pediatric rheumatology clinic.Pediatric rheumatology online journal · 2024Article
- Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study.Archives of rheumatology · 2023Article
- Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2023Review
- Vaccinology in pediatric rheumatology: Past, present and future.Frontiers in pediatrics · 2022Review
- Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs.Mediterranean journal of rheumatology · 2021Article
- Biologics in juvenile idiopathic arthritis-main advantages and major challenges: A narrative review.Archives of rheumatology · 2021Review
- Vaccination in Children With Autoimmune Disorders and Treated With Various Immunosuppressive Regimens: A Comprehensive Review and Practical Guide.Frontiers in immunology · 2021Review
- Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in the era of COVID-19.Rheumatology international · 2020Article
- Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review.Seminars in arthritis and rheumatism · 2020Article
- Vaccination for Children on Biologics.Current rheumatology reports · 2020Review
- Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.Clinical rheumatology · 2020Article
- Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey.Reumatologia · 2020Article
- Vaccination in children with immune-mediated disorders.Jornal de pediatriaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe most effective and concurrently the safest treatment regimen selection is important to provide early control of juvenile idiopathic arthritis (JIA) and to have an acceptable quality of life. The effectivity of biologic agents as well as standard disease-modifying drugs is well documented in treatment of JIA. In spite of their high benefit, these drugs have the risk of serious infections. Herein, we conducted a prospective study to investigate the infectious complications of biologic agents in patients diagnosed with JIA.
methodsPatients on biologic treatment regimen were examined by the pediatric infectious disease specialist in every 2 months during 1-year long.
resultsThroughout the study period, 57% (n:175) of the patients developed infection and 43% (n:132) of them completed this period without any infection. Upper respiratory tract infections which were treated in outpatient clinic were the most common infection. Only three serious infections (two pneumonia, one pleural effusion), which required hospitalization, developed. The infection rate was highest in systemic JIA and lowest in enthesitis-related arthritis (p < 0.001). The total rate of infection development after 1-year period was lowest for etanercept; it was highest for the patients on infliximab treatment (p < 0.001).
conclusionWe comment that the altered immune system of JIA can be responsible from the serious infections irrespective of immunosuppressive therapy. Biologic agents can be safely used in JIA evaluating the loss and benefit statement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.